Testosterone Therapy for Women: Benefits, Evidence, Risks & Appropriate Use

Women produce testosterone through several interconnected endocrine pathways.

The principal sources include the ovaries, adrenal glands, and peripheral tissues.

1. The Ovaries

The ovaries contribute to circulating testosterone production both directly and through the production of androgen precursors.

Ovarian androgen production is influenced by luteinizing hormone (LH), although the regulation of androgen synthesis is more complex than a single hormonal pathway.

2. The Adrenal Glands

These compounds can subsequently be converted into testosterone within peripheral tissues.

3. Peripheral Conversion

A substantial portion of testosterone production in women occurs through the conversion of androgen precursors in tissues outside the ovaries and adrenal glands.

These tissues contain enzymes that regulate local androgen synthesis, activation, and metabolism.

This process is sometimes described as intracrinology, in which hormones are produced and metabolized within tissues where they exert their biological effects.

This creates an important distinction between circulating hormone concentrations and local hormone activity.

Consequently, circulating testosterone concentrations do not necessarily provide a complete picture of androgen activity throughout the body.

One of the most overlooked aspects of female hormone physiology is the widespread distribution of androgen receptors.

Androgen receptors are intracellular receptors that regulate gene expression after binding testosterone or other active androgens.

These receptors are expressed in numerous tissues throughout the female body.

Brain and Central Nervous System

Androgen receptors are present in regions of the brain involved in reproductive behavior, motivation, emotional processing, and other neurological functions.

Testosterone may influence neuronal signaling directly through androgen receptors or indirectly through conversion to estradiol.

These mechanisms provide a biological rationale for studying testosterone’s potential effects on mood, motivation, and cognition.

However, clinical trials have not consistently demonstrated that testosterone supplementation improves these outcomes in women.

Skeletal Muscle

Androgen receptors are expressed in skeletal muscle.

Testosterone influences pathways involved in muscle protein metabolism, cellular signaling, and muscle adaptation.

At sufficiently high concentrations, androgens can produce anabolic effects.

However, the magnitude of these effects depends on dose, duration, and individual physiology.

The anabolic effects observed with supraphysiological testosterone exposure cannot automatically be extrapolated to the much lower doses used in female hormone therapy.

Bone

Androgen receptors are expressed in bone cells, including osteoblasts and osteocytes.

Testosterone may influence skeletal physiology through direct androgen receptor signaling and through conversion to estradiol.

Nevertheless, current clinical evidence does not establish testosterone therapy as an effective treatment for osteoporosis in women.

Adipose Tissue

Androgen receptors are present in adipose tissue.

Androgens participate in pathways related to adipocyte function, fat distribution, and metabolic regulation.

However, the relationship between testosterone and female metabolic health is complex.

For example, elevated androgen concentrations in women with polycystic ovary syndrome may coexist with insulin resistance and adverse metabolic changes.

Therefore, higher testosterone concentrations should not automatically be interpreted as metabolically beneficial.

Cardiovascular System

Androgen receptors are expressed in vascular and cardiac tissues.

Testosterone may influence vascular signaling and other cardiovascular processes.

However, these physiological effects do not establish that testosterone therapy prevents cardiovascular disease.

Long-term cardiovascular safety data in women remain limited.

Skin and Hair Follicles

Androgen receptors influence sebaceous gland activity and hair follicle physiology.

Reproductive Tissues

Androgen receptors are present in the ovaries and several reproductive tissues.

Androgen signaling contributes to normal reproductive physiology and may influence aspects of sexual response.

The widespread distribution of androgen receptors demonstrates that testosterone has biological functions extending far beyond libido.

However, receptor distribution alone does not establish that increasing circulating testosterone concentrations improves the health or function of these tissues.

This distinction becomes particularly important when evaluating claims made about testosterone therapy for energy, muscle preservation, cognition, metabolic health, and longevity.

An interesting aspect of female endocrine physiology is that circulating testosterone concentrations are generally higher than estradiol concentrations when expressed in equivalent units.

For example, typical female testosterone concentrations may range approximately from 15–70 ng/dL, depending on age and laboratory methods.

This corresponds to approximately 150–700 pg/mL.

Estradiol concentrations in premenopausal women fluctuate considerably throughout the menstrual cycle, often ranging from approximately 20–400 pg/mL.

These ranges overlap, particularly around the preovulatory estradiol peak.

Nevertheless, testosterone is generally present at higher circulating mass concentrations than estradiol.

This does not mean testosterone is more biologically important.

Hormone activity depends on receptor affinity, tissue distribution, local metabolism, and circulating concentrations.

Estradiol exerts powerful biological effects at much lower concentrations.

Hormonal importance cannot be determined simply by comparing blood concentrations.

Testosterone concentrations generally decline during the reproductive years, although the pattern varies considerably between individuals.

Unlike estrogen, which undergoes a substantial decline during the menopausal transition, testosterone does not necessarily experience an abrupt decrease at natural menopause.

Some studies suggest that circulating testosterone concentrations remain relatively stable across natural menopause after accounting for age.

This means menopause should not automatically be interpreted as a state of testosterone deficiency.

Natural Menopause Versus Surgical Menopause

Women who undergo bilateral oophorectomy—removal of both ovaries—may experience a more substantial reduction in ovarian androgen production.

Depending on age and hormone status before surgery, this may contribute to changes in sexual desire and other aspects of well-being.

However, symptoms and laboratory findings must still be interpreted individually.

Does Low Testosterone Automatically Require Treatment?

No.

There is currently no universally accepted blood testosterone concentration that establishes a diagnosis of testosterone deficiency in women.

Unlike male hypogonadism, female androgen insufficiency does not have a well-validated diagnostic threshold that reliably predicts who will benefit from testosterone replacement.

A woman may have a relatively low testosterone concentration without experiencing symptoms.

Another woman may report distressing sexual dysfunction despite having testosterone concentrations within the laboratory reference range.

Testosterone levels can help guide treatment safety, but they should not independently determine whether therapy is appropriate.

What Is Hypoactive Sexual Desire Disorder?

Hypoactive sexual desire disorder, or HSDD, involves a persistent or recurrent reduction in sexual desire that causes clinically significant personal distress and is not better explained by another condition or contributing factor.

It is important to distinguish HSDD from simply having a lower level of sexual interest.

Sexual desire varies naturally among individuals and throughout life.

A woman who experiences little sexual desire but is not distressed by it does not necessarily have a disorder requiring medical treatment.

Similarly, reduced sexual desire resulting primarily from relationship conflict, depression, medication effects, or painful intercourse may require treatment directed toward those underlying factors.

What Does Testosterone Actually Improve?

Randomized controlled trials have demonstrated that appropriately dosed systemic testosterone can improve several aspects of sexual function in postmenopausal women with HSDD.

A large systematic review found that testosterone therapy produced approximately one additional satisfying sexual event per month compared with placebo, on average.

This finding is frequently misunderstood.

It does not mean that every woman receiving testosterone will experience only one additional satisfying sexual encounter.

Rather, it represents the average difference between treatment and placebo groups across clinical trials.

Individual responses vary.

Some women experience meaningful improvements in desire and sexual satisfaction, while others experience little or no benefit.

The evidence therefore supports a moderate average treatment effect, not a guaranteed restoration of libido.

How Long Does It Take to Work?

Clinical studies suggest that improvement in sexual desire may begin within approximately four to eight weeks.

Maximum benefits are often observed around 12 weeks.

Some aspects of sexually related distress may continue improving over subsequent months.

If a woman experiences no meaningful clinical improvement after six months of appropriately monitored therapy, treatment should generally be discontinued and alternative explanations reconsidered.

Fatigue, reduced motivation, and difficulty concentrating are among the most common complaints women report during perimenopause and menopause.

These symptoms are frequently attributed to declining testosterone.

However, the relationship is considerably more complicated.

The Biological Rationale

Androgen receptors are present in several tissues involved in neurological function.

Testosterone can influence cellular signaling pathways associated with neurotransmission, reproductive behavior, and other neurological processes.

This creates a plausible biological basis for investigating testosterone’s effects on motivation, mood, and cognition.

However:

Biological plausibility does not establish clinical effectiveness.

What Do Clinical Studies Show?

The Global Consensus Position Statement found insufficient evidence to support testosterone therapy for cognitive enhancement and did not demonstrate a meaningful improvement in general well-being among postmenopausal women.

Some patients receiving testosterone report improvements in energy or motivation.

These experiences should not automatically be dismissed.

However, subjective improvement may reflect multiple influences, including placebo effects, improved sexual well-being, concurrent hormone therapy, changes in sleep, or other lifestyle and medical interventions.

At present, testosterone should not routinely be prescribed solely to treat fatigue or brain fog.

A Broader Clinical Evaluation

Identifying the underlying cause is generally more useful than assuming testosterone is responsible.

Testosterone is an anabolic hormone.

In men, its role in maintaining muscle mass, strength, and body composition is well established.

Women also possess androgen receptors in skeletal muscle.

This raises an important question:

Could testosterone therapy help women preserve muscle mass and physical function as they age?

The Physiological Argument

Testosterone influences muscle physiology through androgen receptor signaling.

At sufficiently high doses, androgens can increase muscle protein accretion.

However, these effects are dose-dependent.

The anabolic effects observed with supraphysiological testosterone exposure cannot automatically be extrapolated to the much lower doses intended to maintain normal female testosterone concentrations.

What Does the Evidence Show in Women?

Clinical trials using physiological testosterone doses have not consistently demonstrated significant improvements in lean body mass, total body fat, or muscle strength in postmenopausal women.

This is an area where clinical marketing frequently extends beyond the available evidence.

Why Muscle Preservation Still Matters

The lack of evidence supporting testosterone for muscle preservation does not diminish the importance of maintaining skeletal muscle during aging.

Resistance training, adequate protein intake, appropriate energy intake, and management of underlying medical conditions remain foundational interventions.

For women undergoing medical weight loss, preserving muscle becomes particularly important because weight reduction may involve losses of both fat and lean tissue.

Testosterone should not replace these established strategies.

Testosterone contributes to skeletal physiology through androgen receptor signaling and through its conversion to estradiol.

Both pathways are biologically relevant to bone metabolism.

However, estrogen remains a major regulator of bone remodeling in women.

Can Testosterone Prevent Osteoporosis?

Current clinical trials have not established that physiological testosterone therapy meaningfully improves bone mineral density or reduces fracture risk in postmenopausal women.

Therefore, testosterone should not be prescribed specifically to prevent or treat osteoporosis.

Women with low bone density should undergo an appropriate evaluation and receive evidence-based interventions, which may include resistance exercise, adequate calcium and vitamin D intake, estrogen therapy when appropriate, or osteoporosis-specific medications.

Laboratory evaluation can provide useful information, but interpreting testosterone concentrations in women requires several considerations.

Total Testosterone

Total testosterone measures testosterone circulating in the blood, including hormone bound to proteins and the smaller unbound fraction.

It is commonly used as the principal laboratory measurement when evaluating and monitoring testosterone therapy.

However, testosterone concentrations in women are much lower than in men.

Some laboratory assays lack sufficient sensitivity and accuracy at these concentrations.

When available, liquid chromatography–tandem mass spectrometry (LC-MS/MS) is generally preferred for accurate measurement.

Free Testosterone

Free testosterone represents the small fraction of circulating testosterone that is not bound to transport proteins.

Although free testosterone may provide additional context, direct free testosterone immunoassays can be unreliable at female concentrations.

Calculated free testosterone, using total testosterone and sex hormone-binding globulin, may be more informative in selected circumstances.

Sex Hormone-Binding Globulin (SHBG)

SHBG is a protein that binds circulating sex hormones.

Higher SHBG concentrations generally reduce the proportion of circulating testosterone that is unbound.

A woman with relatively normal total testosterone but elevated SHBG may have a lower calculated free testosterone concentration.

However, this finding does not independently establish a need for testosterone therapy.

Is There an Optimal Testosterone Level for Women?

This is an important area of misunderstanding.

There is no scientifically validated universal testosterone concentration that defines optimal sexual function, energy, or well-being in women.

Reference ranges also vary by laboratory, assay, age, and reproductive status.

When testosterone therapy is prescribed, the objective is generally to mitigate symptoms of low testosterone symptoms without negative side effects.

The goal is not to increase testosterone to the highest possible concentration or to pursue a predetermined number regardless of symptoms.

Laboratory testing is particularly important for preventing excessive androgen exposure.

Several testosterone formulations are used in clinical practice.

However, these formulations differ substantially in their pharmacokinetics, ability to adjust dosing, and available safety evidence.

1. Transdermal Testosterone

Transdermal testosterone is applied to the skin, typically as a gel or cream.

It is the formulation most strongly supported by clinical guidelines for women with HSDD.

In the United States, there is currently no FDA-approved testosterone product specifically indicated for women.

Clinicians may prescribe an FDA-approved male transdermal product off-label at an appropriately reduced dose. This is can be very challenging, because a very small amount of product much be applied and thus small variations in the volume of product can lead to significant variation of dose.

Careful dosing is essential because standard male formulations contain substantially more testosterone than women generally require.

Transdermal products also require precautions to prevent unintended transfer to children, partners, or pets through skin contact.

2. Compounded Testosterone Creams, Oral Formulations, and Injectables

Compounded testosterone preparations may allow individualized concentrations and dosing.

However, compounded medications are not FDA-approved and do not undergo the same premarket evaluation for safety, effectiveness, manufacturing consistency, and quality as FDA-approved products.

Major clinical guidelines generally discourage compounded testosterone because of limited evidence regarding product consistency, efficacy, and safety.

When an appropriate FDA-approved formulation can be used off-label, it is generally preferred.

If compounding is considered because an appropriate approved formulation cannot meet a patient’s medical needs, the limitations and potential risks should be discussed.

3. Testosterone Injections

Injectable testosterone can produce significant fluctuations in circulating concentrations depending on the formulation, dose, and administration interval. Especially when using FDA-approved formulations used for men testosterone replacement.

Although injections are used in some clinical practices, high-quality evidence supporting injectable testosterone for female HSDD is limited.

Major international guidelines do not recommend injectable regimens that produce testosterone concentrations above the normal female physiological range.

Small doses do not automatically guarantee physiological exposure.

Careful monitoring is particularly important if an injectable formulation is considered.

4. Testosterone Pellets

Testosterone pellets are implanted beneath the skin and release hormone over an extended period.

Their primary limitation is reduced flexibility.

Once implanted, the dose cannot be rapidly adjusted or discontinued.

Some pellet regimens may produce supraphysiological testosterone concentrations.

Because of these concerns and the limited quality of supporting evidence, major guidelines generally recommend against testosterone pellets for women.

5. Oral, Sublingual, and Buccal Testosterone

Oral testosterone formulations differ considerably in their absorption, metabolism, and pharmacokinetic profiles.

Traditional swallowed testosterone formulations undergo gastrointestinal absorption and hepatic first-pass metabolism. Certain oral androgen formulations have been associated with unfavorable changes in lipid profiles, particularly reductions in HDL cholesterol. For this reason, conventional oral testosterone is generally not recommended for women.

However, not all testosterone preparations administered through the mouth are pharmacologically equivalent.

Compounded sublingual and buccal testosterone formulations are designed to facilitate absorption through the oral mucosa or lymphatic absorption, allowing some testosterone to enter systemic circulation while bypassing initial hepatic first-pass metabolism.

These preparations may provide clinically meaningful testosterone exposure, and studies of sublingual testosterone have demonstrated biological activity and potential benefits in aspects of female sexual response.

Clinical experience has also suggested potential benefits in selected patients.

Nevertheless, compounded sublingual and buccal formulations have several important limitations.

Absorption may vary depending on the formulation, administration technique, and amount of medication swallowed. Sublingual testosterone may also produce relatively rapid increases in circulating testosterone concentrations followed by a decline, potentially creating greater hormonal fluctuations than transdermal preparations.

Furthermore, although these formulations may reduce initial hepatic exposure, their long-term cardiovascular, metabolic, and androgenic safety profiles have not been adequately established.

The distinction is important: avoiding first-pass metabolism may offer a pharmacological advantage over conventional swallowed testosterone, but it does not independently establish superior efficacy or safety.

Compounded oral-mucosal or other oral formulations of testosterone preparations are not FDA-approved, and high-quality clinical evidence supporting their routine use in women remains limited.

Current international guidelines continue to favor appropriately dosed transdermal testosterone when systemic treatment is indicated.

However, sublingual and buccal preparations represent alternative delivery approaches that warrant further investigation, particularly regarding absorption consistency, dose optimization, clinical outcomes, and long-term safety.

Testosterone therapy is not without risk.

The likelihood and severity of adverse effects depend on several factors, including dose, formulation, treatment duration, individual sensitivity, and circulating hormone concentrations.

Androgenic Side Effects

These effects may occur even when treatment is intended to maintain physiological concentrations, although they become more concerning with excessive androgen exposure.

Voice Deepening and Clitoral Enlargement

More significant androgen exposure may result in:

• Deepening of the voice
• Clitoral enlargement

These effects are particularly concerning because they may be irreversible.

Patients should be informed of these risks before beginning treatment.

Cardiovascular and Metabolic Risks

The cardiovascular safety of testosterone therapy in women remains an important area of ongoing investigation.

Short-term studies using physiological doses of nonoral testosterone have generally not demonstrated major adverse changes in several cardiovascular risk markers.

However, these findings have important limitations.

Many trials excluded women with substantial cardiovascular or metabolic risk.

Most were relatively short in duration.

Consequently, the available evidence cannot establish the long-term cardiovascular safety of testosterone therapy, particularly in higher-risk populations.

Oral testosterone has demonstrated less favorable effects on lipid metabolism and is generally discouraged.

Testosterone, Breast Health, and Breast Cancer Risk

The relationship between testosterone and breast cancer is more complex than traditionally assumed.

Testosterone can influence breast tissue through direct androgen receptor signaling and through its conversion into estradiol by the enzyme aromatase.

Androgen receptors are widely expressed in normal breast tissue and many breast cancers. Depending on the cellular environment and molecular characteristics of the tumor, androgen signaling may influence breast cell proliferation and other biological processes.

Interestingly, some observational studies have suggested that testosterone therapy may be associated with a reduced incidence of breast cancer.

A 2019 prospective cohort study published in BMC Cancer evaluated 1,267 women receiving subcutaneous testosterone implants, sometimes combined with the aromatase inhibitor anastrozole.

Researchers observed approximately 39% fewer cases of invasive breast cancer than expected based on age-matched population data.

A separate study published in 2021 evaluated 2,377 women receiving testosterone or testosterone combined with estradiol implants.

That study also reported a lower incidence of invasive breast cancer compared with historical population data, with an approximately 35% relative difference.

These findings raise an intriguing possibility that androgen signaling may have protective effects in certain breast tissue environments.

However, important limitations must be recognized.

Both studies were observational and lacked randomized control groups. Differences in patient characteristics, breast cancer screening, concurrent hormone treatments, and other factors may have influenced the results.

Additionally, some women received aromatase inhibitors or concurrent estrogen therapy, complicating interpretation of testosterone’s independent effects.

These studies suggest a potential protective association, but they do not establish that testosterone therapy prevents breast cancer.

Short-term randomized trials of physiological transdermal testosterone have generally not demonstrated an increased breast cancer risk. However, long-term safety remains insufficiently established.

Further randomized controlled trials are needed to determine whether testosterone has a protective, neutral, or potentially harmful effect on breast cancer risk in different populations.

For now, testosterone should not be prescribed specifically for breast cancer prevention, but the possibility of protective effects represents an important area of ongoing research.

Pregnancy

Testosterone therapy should generally be avoided during pregnancy and in women who may become pregnant without appropriate pregnancy prevention.

Androgen exposure may adversely affect fetal development.

This is one of the most common concerns women express when considering testosterone therapy.

The answer depends substantially on androgen exposure.

Women naturally produce testosterone and require androgen signaling for normal physiology.

Restoring or maintaining physiological concentrations is fundamentally different from exposing the body to testosterone levels typically observed in men.

However, physiological dosing does not eliminate all androgen-related risks.

Individual tissue sensitivity varies.

A woman may experience acne, hair changes, or other androgenic symptoms even without dramatically elevated blood testosterone concentrations.

Increasing testosterone simply because a patient has not experienced a desired improvement is not an appropriate strategy when concentrations are already within the upper physiological range.

Appropriate monitoring involves more than periodically checking a testosterone concentration.

It requires ongoing assessment of symptoms, adverse effects, and the continued justification for treatment.

Before Treatment

After Starting Treatment

Clinical guidelines generally recommend repeating total testosterone approximately three to six weeks after treatment initiation.

Additional testing is appropriate after dose adjustments.

Once treatment is stable, testosterone concentrations are commonly reassessed every four to six months.

When Should Treatment Be Stopped?

Continued treatment should depend on a favorable balance of benefits and risks—not simply on maintaining a laboratory value.

A common mistake in hormone optimization is evaluating testosterone independently from the broader endocrine system.

Female sexual function and well-being are influenced by multiple interacting factors.

Estrogen

Estradiol contributes to vaginal tissue health, lubrication, genital blood flow, and other aspects of sexual function.

Estrogen deficiency may cause vaginal dryness, painful intercourse, and genitourinary symptoms.

Testosterone does not replace appropriate treatment of estrogen deficiency.

Progesterone

Progesterone has important reproductive functions and may influence sleep and other neurological processes.

Its role in hormone therapy depends on factors such as menopausal status, uterine status, and the estrogen regimen being used.

Thyroid Hormones

Thyroid dysfunction can contribute to fatigue, changes in mood, weight fluctuations, and sexual symptoms.

These symptoms may overlap with complaints sometimes attributed to testosterone.

Cortisol and Stress Physiology

Chronic stress, sleep deprivation, and psychological distress may influence sexual desire and overall well-being.

These factors should be considered when evaluating women with persistent symptoms.

Metabolic Health

Insulin resistance, obesity, and metabolic disease can influence SHBG concentrations and circulating androgen availability.

However, changes in androgen concentrations associated with metabolic disease do not necessarily indicate that testosterone therapy is appropriate.

Successful hormone care requires identifying which physiological systems are contributing to a patient’s symptoms rather than assuming every symptom reflects a hormone deficiency.

The term hormone optimization is frequently used in functional and longevity medicine.

However, optimization can mean different things depending on the clinical setting.

In some practices, it refers to correcting established hormone deficiencies.

In others, it refers to adjusting hormone concentrations toward predetermined targets intended to improve energy, physical performance, sexual function, or aging-related outcomes.

These approaches are not equivalent.

What Does the Evidence Support?

For women with postmenopausal HSDD, carefully monitored testosterone therapy may provide meaningful benefits.

For women seeking improved energy, muscle growth, cognitive performance, or longevity, the evidence does not currently establish that increasing testosterone within or above the normal physiological range produces consistent clinical benefits.

This distinction is particularly important because testosterone therapy can produce adverse effects when concentrations become excessive.

Is More Testosterone Better?

Not always.

The evidence is lacking that higher testosterone concentrations within the normal female range consistently produce better clinical outcomes.

Likewise, there is no established evidence that supraphysiological testosterone exposure improves long-term health in women.

Hormone optimization should not be confused with maximizing hormone concentrations.

The objective should be meaningful improvement in patient health and function—not simply achieving a laboratory target.

Determining whether a woman may benefit from testosterone therapy requires more than evaluating a laboratory result or establishing a diagnosis of hypoactive sexual desire disorder (HSDD).

Traditional clinical guidelines primarily support testosterone therapy for postmenopausal women experiencing HSDD. However, contemporary approaches to individualized hormone care also consider broader concerns involving symptoms, quality of life, and physiological changes associated with aging.

These symptoms may warrant a comprehensive hormonal and metabolic evaluation, but they do not independently establish testosterone deficiency or demonstrate that testosterone treatment will be effective.

An Individualized Approach to Hormone Optimization

At R2 Medical Clinic, hormone optimization begins with understanding the patient rather than treating an isolated laboratory value.

A comprehensive assessment considers symptoms, medical history, menopausal status, lifestyle, metabolic health, and relevant laboratory findings.

The objective is to identify potentially modifiable factors contributing to a woman’s symptoms and determine which interventions may improve her quality of life.

Testosterone is one component of this evaluation.

Because androgen receptors are widely distributed throughout the female body, testosterone participates in physiological processes extending beyond sexual function. However, its widespread biological activity does not necessarily mean supplementation will improve each of these functions.

For women experiencing persistent symptoms despite appropriate evaluation and management of other contributing factors, testosterone therapy may be discussed as an individualized, off-label treatment consideration.

This discussion should acknowledge that evidence supporting testosterone for energy, cognition, muscle preservation, body composition, and general well-being remains limited.

Symptom Management Versus Laboratory Optimization

An important distinction in hormone optimization is that laboratory reference ranges describe hormone concentrations within a population. They do not necessarily establish the ideal concentration for every individual.

However, there is currently no validated testosterone threshold that reliably predicts symptom improvement in women.

Consequently, treatment decisions should not be based solely on whether testosterone falls near the lower end of a laboratory reference range.

Similarly, achieving a higher testosterone concentration should not be considered evidence of successful treatment.

Shared Decision-Making and Appropriate Expectations

Individualized hormone optimization requires informed decision-making.

Patients should understand which potential benefits are supported by randomized clinical trials, which remain under investigation, and which are based primarily on clinical observations.

For women with postmenopausal HSDD, testosterone therapy has demonstrated meaningful benefits in sexual function.

For other symptoms, the evidence is less definitive, and treatment should not be presented as an established solution.

The goal of individualized hormone care is not simply to normalize a laboratory value or maximize hormone concentrations. It is to understand the patient’s symptoms, identify potentially contributing physiological factors, and develop a treatment strategy that balances quality of life, clinical evidence, and long-term safety.

Who May Not Be an Appropriate Candidate?

Treatment should be individualized rather than routinely prescribed based on age or a single laboratory result.

Testosterone is an important component of female endocrine physiology.

It is generally present at higher circulating concentrations than estradiol and acts through androgen receptors distributed throughout the brain, skeletal muscle, bone, adipose tissue, cardiovascular system, skin, and reproductive tissues.

Its biological functions extend well beyond sexual desire.

However, recognizing testosterone’s widespread physiological activity does not mean that every woman with fatigue, low motivation, weight gain, or reduced muscle mass will benefit from testosterone therapy.

The strongest clinical evidence supports its use in appropriately selected postmenopausal women experiencing hypoactive sexual desire disorder.

For other commonly promoted benefits—including improved energy, cognitive performance, muscle preservation, weight loss, and longevity—the evidence remains insufficient to support routine treatment.

The distinction between established benefits and emerging hypotheses is essential.

Good hormone care is not about maximizing testosterone. It is about understanding the patient’s symptoms, identifying contributing factors, using treatment when appropriate, and carefully balancing potential benefits against risks.

Women deserve individualized medical care that acknowledges both the potential value of testosterone therapy and the limitations of current research.

At R2 Medical Clinic in Denver, Colorado, we recognize that women’s hormone health is complex and highly individualized.

Symptoms involving sexual function, energy, sleep, body composition, and overall well-being often reflect interactions among multiple physiological systems.

Our approach begins with a comprehensive evaluation of symptoms, medical history, relevant laboratory findings, and potential contributing factors.

When testosterone therapy is considered, we emphasize individualized treatment decisions, informed consent, appropriate dosing, and ongoing clinical monitoring.

We also recognize the importance of distinguishing treatments supported by established clinical evidence from those whose potential benefits remain under investigation.

Our goal is to help women better understand their hormone health and make informed decisions about available treatment options.

If you are experiencing changes in sexual desire or other symptoms that may be related to hormonal changes, R2 Medical Clinic can help you explore potential causes and determine which treatment options may be appropriate for your individual needs.